Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON)
This study has been terminated.
( IDMC recommendation for safety concerns )
Study NCT01351675 Information provided by Reata Pharmaceuticals, Inc.
First Received on December 3, 2010. Last Updated on November 1, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2
Additional conditions recognized in this trial
Kidney Failure, Chronic
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Interventions listed in this trial
Bardoxolone Methyl: 20 mg
Sponsors listed in this trial
Reata Pharmaceuticals, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers